interstitial lung disease

      Interstitial lung disease GudangMovies21 Rebahinxxi LK21

      Interstitial lung disease (ILD), or diffuse parenchymal lung disease (DPLD), is a group of respiratory diseases affecting the interstitium (the tissue) and space around the alveoli (air sacs) of the lungs. It concerns alveolar epithelium, pulmonary capillary endothelium, basement membrane, and perivascular and perilymphatic tissues. It may occur when an injury to the lungs triggers an abnormal healing response. Ordinarily, the body generates just the right amount of tissue to repair damage, but in interstitial lung disease, the repair process is disrupted, and the tissue around the air sacs (alveoli) becomes scarred and thickened. This makes it more difficult for oxygen to pass into the bloodstream. The disease presents itself with the following symptoms: shortness of breath, nonproductive coughing, fatigue, and weight loss, which tend to develop slowly, over several months. The average rate of survival for someone with this disease is between three and five years. The term ILD is used to distinguish these diseases from obstructive airways diseases.
      There are specific types in children, known as children's interstitial lung diseases. The acronym ChILD is sometimes used for this group of diseases. In children, the pathophysiology involves a genetic component, exposure-related injury, autoimmune dysregulation, or all of the components.
      Thirty to 40% of those with interstitial lung disease eventually develop pulmonary fibrosis which has a median survival of 2.5-3.5 years. Idiopathic pulmonary fibrosis is interstitial lung disease for which no obvious cause can be identified (idiopathic) and is associated with typical findings both radiographic (basal and pleural-based fibrosis with honeycombing) and pathologic (temporally and spatially heterogeneous fibrosis, histopathologic honeycombing, and fibroblastic foci).
      In 2015, interstitial lung disease, together with pulmonary sarcoidosis, affected 1.9 million people. They resulted in 122,000 deaths.


      Causes



      ILD may be classified as to whether its cause is not known (idiopathic) or known (secondary).


      = Idiopathic

      =
      Idiopathic interstitial pneumonia is the term given to ILDs with an unknown cause. They represent the majority of cases of interstitial lung diseases (up to two-thirds of cases). They were subclassified by the American Thoracic Society in 2002 into 7 subgroups:

      Idiopathic pulmonary fibrosis (IPF): the most common subgroup, representing more than 30% of ILD
      Desquamative interstitial pneumonia (DIP)
      Acute interstitial pneumonia (AIP): also known as Hamman-Rich syndrome
      Nonspecific interstitial pneumonia (NSIP)
      Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD)
      Cryptogenic organizing pneumonia (COP): also known by the older name bronchiolitis obliterans organizing pneumonia (BOOP)
      Lymphoid interstitial pneumonia (LIP)


      = Secondary

      =
      Secondary ILDs are those diseases with a known etiology, including:


      Connective tissue and autoimmune diseases


      Connective tissue related disease represents approximately 25% of all cases of ILD.

      Sarcoidosis
      Rheumatoid arthritis
      Systemic lupus erythematosus
      Systemic sclerosis
      Polymyositis
      Dermatomyositis
      Antisynthetase syndrome


      Inhaled substances (pneumoconiosis)


      Inorganic
      Silicosis
      Asbestosis
      Berylliosis
      Industrial printing chemicals (e.g. carbon black, ink mist)
      Organic
      Hypersensitivity pneumonitis (extrinsic allergic alveolitis), representing approximately 15% of cases of ILD.


      Drug-induced


      Antibiotics (e.g., nitrofurantoin and sulfa drugs)
      Chemotherapeutic drugs
      Antiarrhythmic agents
      Cigarette smoking
      Smoking-related interstitial fibrosis (SRIF) is an example of a type of interstitial lung disease known to be caused by smoking.


      Infection


      Coronavirus disease 2019 (COVID-19)
      Atypical pneumonia
      Pneumocystis pneumonia (PCP)
      Tuberculosis
      Chlamydia trachomatis
      Respiratory syncytial virus


      Malignancy


      Lymphangitic carcinomatosis


      Childhood interstitial lung disease and ILD predominately in children



      Diffuse developmental disorders
      Growth abnormalities and deficient alveolarisation
      Infant conditions of undefined cause
      ILD related to alveolar surfactant region


      Diagnosis



      Diagnosis of ILD involves assessing the signs and symptoms as well as a detailed history investigating occupational exposures. ILD usually presents with dyspnea, worsening exercise intolerance and 30-50% of those with ILD have a chronic cough. On examination, velcro crackles, in which the crackles compare to the sound of velcro being unfastened, are common in ILD. Pulmonary function tests usually show a restrictive defect with decreased diffusion capacity of carbon monoxide (DLCO) indicating reduced alveolar to blood capillary transport. Pulmonary function testing is indicated for all people with ILD and the FVC loss and DLCO is prognostic, with an FVC loss of greater than 5% per year associated with a poor prognosis in fibrosis subtypes of ILD.
      A chest x-ray is 63% sensitive and 93% specific for ILD. With advances in computed tomography, CT scans of the chest have supplanted lung biopsy as the preferred diagnostic test for ILD. A thoracic CT scan is 91% sensitive and 71% specific for ILD. In higher income countries, less than 10% of people with ILD undergo a lung biopsy as part of the diagnostic evaluation.
      A lung biopsy may be required if the clinical history and imaging are not clearly suggestive of a specific diagnosis or malignancy cannot otherwise be ruled out. Surgical lung biopsy or via a video-assisted thoracoscopic surgery (VATS) biopsy is associated with a mortality rate up to 1-2%. A bronchoscopic transbronchial cryobiopsy, in which a camera is introduced into the airways followed by rapid freezing of an area of lung tissue prior to biopsy is associated a lower complication rate and a much lower mortality rate compared to VATS or surgical biopsy with near comparable diagnostic accuracy. There are four types of histopathologic patterns seen in ILD: usual interstitial pneumonia, non-specific interstitial pneumonia, organizing pneumonia, and diffuse alveolar damage. There is significant overlap of the histopathological and radiologic features of each ILD type making diagnosis challenging; even with lung biopsy, 15% of cases of ILD cannot be classified.


      = Pulmonary function testing

      =
      Most patients with suspected ILD are likely to undergo complete pulmonary function testing. These tests are useful in diagnosis and determining severity of the disease.
      Although there is large diversity in interstitial lung disease, most follow a restrictive pattern. Restrictive defects are defined by decreased TLC (total lung capacity), RV (residual volume), FVC (forced vital capacity) and FEV1 (forced expiratory volume in one second). As both FVC and FEV1 are reduced, the FVC to FEV1 ratio remains normal or is increased.
      As disease progression increases and the lungs become stiffer lung volumes will continue to decrease; lower TLC, RV, FVC and FEV1 scores are associated with a more severe disease progression and poorer prognosis.


      = X-ray and CT (computed tomography)

      =
      Chest radiography is usually the first test to detect interstitial lung diseases, but the chest radiograph can be normal in up to 10% of patients, especially early in the disease process.
      High-resolution CT of the chest is the preferred modality and differs from routine CT of the chest. Conventional (regular) CT chest examines 7–10 mm slices obtained
      at 10 mm intervals; high resolution CT examines 1–1.5 mm slices at 10 mm intervals using a high-spatial-frequency reconstruction algorithm. The HRCT therefore provides approximately 10 times more resolution than the conventional CT chest, allowing the HRCT to elicit details that cannot otherwise be visualized.
      Radiologic appearance alone, however, is not adequate and should be interpreted in the clinical context, keeping in mind the temporal profile of the disease process.
      Interstitial lung diseases can be classified according to radiologic patterns.


      Pattern of opacities


      Consolidation
      Acute:
      Alveolar hemorrhage syndromes
      Acute eosinophilic pneumonia
      Acute interstitial pneumonia
      Cryptogenic organizing pneumonia
      Chronic:
      Chronic eosinophilic pneumonia
      Cryptogenic organizing pneumonia
      Lymphoproliferative disorders
      Pulmonary alveolar proteinosis
      Sarcoidosis
      Linear or reticular opacities
      Acute:
      Pulmonary edema
      Chronic:
      Idiopathic pulmonary fibrosis
      Connective tissue-associated interstitial lung diseases
      Asbestosis
      Sarcoidosis
      Hypersensitivity pneumonitis
      Drug-induced lung disease
      Small nodules
      Acute:
      Hypersensitivity pneumonitis
      Chronic:
      Hypersensitivity pneumonitis
      Sarcoidosis
      Silicosis
      Coal workers pneumoconiosis
      Respiratory bronchiolitis
      Alveolar microlithiasis
      Cystic airspaces
      Chronic:
      Pulmonary Langerhans cell histiocytosis
      Pulmonary lymphangioleiomyomatosis
      Honeycomb lung caused by idiopathic pulmonary fibrosis (IPF) or other diseases
      Ground glass opacities
      Acute:
      Alveolar hemorrhage syndromes
      Pulmonary edema
      Hypersensitivity pneumonitis
      Acute inhalational exposures
      Drug-induced lung diseases
      Acute interstitial pneumonia
      Chronic:
      Nonspecific interstitial pneumonia
      Respiratory bronchiolitis-associated interstitial lung disease
      Desquamative interstitial pneumonia
      Drug-induced lung diseases
      Pulmonary alveolar proteinosis
      Thickened alveolar septa
      Acute:
      Pulmonary edema
      Chronic:
      Lymphangitic carcinomatosis
      Pulmonary alveolar proteinosis
      Sarcoidosis
      Pulmonary veno-occlusive disease


      Distribution


      Upper lung predominance
      Pulmonary Langerhans cell histiocytosis
      Silicosis
      Coal workers pneumoconiosis
      Carmustine-related pulmonary fibrosis
      Respiratory broncholitis associated with interstitial lung disease
      Lower lung predominance
      Idiopathic pulmonary fibrosis
      Pulmonary fibrosis associated with connective tissue diseases (ILD-CTD)
      Asbestosis
      Chronic aspiration
      Central predominance (perihilar)
      Sarcoidosis
      Berylliosis
      Peripheral predominance
      Idiopathic pulmonary fibrosis
      Chronic eosinophilic pneumonia
      Cryptogenic organizing pneumonia


      Associated findings


      Pleural effusion or thickening
      Pulmonary edema
      Connective tissue diseases
      Asbestosis
      Lymphangitic carcinomatosis
      Lymphoma
      Lymphangioleiomyomatosis
      Drug-induced lung diseases
      Lymphadenopathy
      Sarcoidosis
      Silicosis
      Berylliosis
      Lymphangitic carcinomatosis
      Lymphoma
      Lymphocytic interstitial pneumonia


      = Genetic testing

      =
      For some types of paediatric ILDs and few forms adult ILDs, genetic causes have been identified. These may be identified by blood tests. For a limited number of cases, this is a definite advantage, as a precise molecular diagnosis can be done; frequently then there is no need for a lung biopsy. Testing is available for


      ILDs related to alveolar surfactant region


      Surfactant protein B deficiency (mutations in SFTPB)
      Surfactant protein C deficiency (mutations in SFTPC)
      ABCA3 deficiency (mutations in ABCA3)
      Brain–lung–thyroid syndrome (Mutations in TTF1)
      Congenital pulmonary alveolar proteinosis (mutations in CSFR2A and/or CSFR2B)


      Diffuse developmental disorder


      Alveolar capillary dysplasia (mutations in FoxF1)


      Idiopathic pulmonary fibrosis


      Mutations in telomerase reverse transcriptase (TERT)
      Mutations in telomerase RNA component (TERC)
      Mutations in the regulator of telomere elongation helicase 1 (RTEL1)
      Mutations in poly(A)-specific ribonuclease (PARN)


      Treatment


      ILD is not a single disease but encompasses many different pathological processes, hence treatment is different for each disease. If a specific occupational exposure cause is found, the person should avoid that environment. If a drug cause is suspected, that drug should be discontinued.


      = Oxygen therapy

      =
      Oxygen therapy at home is recommended in those with significantly low oxygen levels. Oxygen therapy in ILD is associated with improvements in quality of life but reductions in mortality are uncertain. Long-term oxygen therapy can be beneficial to people with ILD and hypoxemia to enhance gas exchange, lessen dyspnea, and increase physical activity.


      = Pulmonary rehabilitation

      =
      Pulmonary rehabilitation appears to be useful with the benefits being sustainable longer term with improvements in exercise capacity (as measured by a six minute walking test), dyspnea, and quality of life.


      = Lung transplantation

      =
      Lung transplantation is an option if the ILD progresses despite therapy in appropriately selected patients with no other contraindications. Life expectancy after lung transplant is 5.2 years in those with idiopathic interstitial pneumonias (including idiopathic pulmonary fibrosis) and 6.7 years in those with other types of ILD.


      = Medications

      =
      The antifibrotics pirfenidone and nintedanib have been shown to slow the decline in lung function (as measured by forced vital capacity [FVC]) in those with ILD compared to placebo. Pirfenidone was associated with a 45% less decline in FVC at 52 weeks compared to placebo in a trial involving people with idiopathic pulmonary fibrosis, and was associated with a slower FVC decline in those with progressive pulmonary fibrosis. Nintedanib was also associated with a slower FVC decline and increased mean survival in people with ILD.
      The immunomodulator tocilizumab has a benefit in scleroderma associated ILD by helping to preserve lung function (as measured by FVC) at 48 weeks. The immunomodulators cyclophosphamide, mycophenolate mofetil and rituximab all showed improved lung function (as measured by % predicted FVC) compared to placebo in systemic sclerosis or scleroderma associated ILD.
      The inhaled vasodilator treprostinil (a synthetic prostacyclin which acts as a prostaglandin I2 analogue) is indicated in the treatment of pulmonary hypertension secondary to interstitial lung disease and is associated with improved exercise capacity as measured by a 6-minute walk test.


      = Supportive care

      =
      Those with ILD should stop smoking cigarettes if they smoke. Vaccinations against pneumococcus, Covid-19, RSV and influenza are indicated in all those with ILD. Short acting opiates are known to improve breathlessness symptoms in those with end stage lung disease. The opiate agonist-antagonist nalbuphine and morphine are also known to improve coughing in those with ILD and other end stage lung diseases.


      Prognosis


      The median survival in idiopathic pulmonary fibrosis is 3-3.5 years. In those who receive a lung transplant, the medial survival in idiopathic pulmonary fibrosis is 5.2 years, as compared to 6.7 years in those with other types of ILD. ILD is associated with a 3-fold increased risk of lung cancer.


      References




      External links



      00736 at CHORUS

    Kata Kunci Pencarian: interstitial lung disease

    interstitial lung disease adalahinterstitial lung disease radiologyinterstitial lung disease icd 10interstitial lung disease pdfinterstitial lung disease ncbiinterstitial lung disease radiology assistantinterstitial lung disease classificationinterstitial lung disease ct scaninterstitial lung disease pathophysiologyinterstitial lung disease xray Search Results

    interstitial lung disease

    Daftar Isi

    Interstitial lung disease - Symptoms and causes - Mayo Clinic

    Nov 23, 2024 · Interstitial lung disease seems to occur when an injury to your lungs causes a healing response that isn't proper. Ordinarily, your body creates just the right amount of tissue …

    Interstitial Lung Disease: Stages, Symptoms & Treatment

    Interstitial lung disease (ILD) is a term for a group of over 200 conditions that cause inflammation and scarring in your lungs. ILD damages the tissues between the small air sacs in your lungs …

    Interstitial lung disease - Diagnosis and treatment - Mayo Clinic

    Nov 23, 2024 · Finding the cause of interstitial lung disease can be challenging, and sometimes the cause can't be found. Many conditions fall into the category of ILD. In addition, the …

    Interstitial Lung Disease - American Lung Association

    Interstitial lung disease (ILD) is an umbrella term used for a large group of diseases that cause scarring (fibrosis) of the lungs. The scarring causes stiffness in the lungs which makes it …

    Interstitial lung disease - Wikipedia

    Interstitial lung disease (ILD), or diffuse parenchymal lung disease (DPLD), [3] is a group of respiratory diseases affecting the interstitium (the tissue) and space around the alveoli (air …

    Interstitial Lung Disease: Symptoms, Causes, Types - Healthline

    Nov 8, 2022 · Interstitial lung disease includes over 200 different conditions that cause inflammation and scarring around the balloon-like air sacs in your lungs, called the alveoli.

    Interstitial Lung Disease: Pulmonary Fibrosis - Johns Hopkins …

    Interstitial lung disease refers to a group of about 100 chronic lung disorders characterized by inflammation and scarring that make it hard for the lungs to get enough oxygen. The scarring …

    Interstitial Lung Disease - StatPearls - NCBI Bookshelf

    Jul 31, 2023 · Interstitial lung disease (ILD), sometimes called diffused parenchymal diseases, describes a heterogeneous collection of distinctive lung disorders classified on the grounds of …

    Interstitial Lung Disease (ILD) - WebMD

    Nov 3, 2021 · Interstitial lung disease (ILD) is a group of many lung conditions. All interstitial lung diseases affect the interstitium, a part of your lungs. The interstitium is a lace-like network of...

    Interstitial Lung Disease (ILD): Causes & Treatment - Verywell …

    Apr 1, 2024 · This article will review some of the more common forms of interstitial lung disease, their causes and risk factors, available treatments, and how ILD can impact your overall well …